These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
56 related articles for article (PubMed ID: 21036746)
21. Genomic landscape of synchronous tubulovillous adenoma and multiple non-familial colon cancers from a single patient. Kim K; Choi SH; Lee J; Lee WS Cancer Genet; 2019 Feb; 231-232():54-61. PubMed ID: 30803558 [TBL] [Abstract][Full Text] [Related]
22. Mixed adenoneuroendocrine carcinoma of the colon: molecular pathogenesis and treatment. Vanacker L; Smeets D; Hoorens A; Teugels E; Algaba R; Dehou MF; De Becker A; Lambrechts D; De Greve J Anticancer Res; 2014 Oct; 34(10):5517-21. PubMed ID: 25275049 [TBL] [Abstract][Full Text] [Related]
23. Analysis of KRAS Mutations of Exon 2 Codons 12 and 13 by SNaPshot Analysis in Comparison to Common DNA Sequencing. Zinsky R; Bölükbas S; Bartsch H; Schirren J; Fisseler-Eckhoff A Gastroenterol Res Pract; 2010; 2010():789363. PubMed ID: 21197450 [TBL] [Abstract][Full Text] [Related]
24. Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment. Moorcraft SY; Jones T; Walker BA; Ladas G; Kalaitzaki E; Yuan L; Begum R; Eltahir Z; Wotherspoon A; Montero-Fernandez A; Teixeira Mendes LS; Gonzalez de Castro D; Wilson SH; Proszek P; To YM; Hawkes E; Roy A; Cunningham D; Rao S; Watkins D; Starling N; Bowcock AM; Chau I Oncotarget; 2017 Sep; 8(39):64999-65008. PubMed ID: 29029407 [TBL] [Abstract][Full Text] [Related]
25. IDH2 Mutation in a Patient with Metastatic Colon Cancer. Zhang BM; Aleshin A; Lin CY; Ford J; Zehnder JL; Suarez CJ N Engl J Med; 2017 May; 376(20):1991-2. PubMed ID: 28514606 [No Abstract] [Full Text] [Related]
26. Hypermutable DNA chronicles the evolution of human colon cancer. Naxerova K; Brachtel E; Salk JJ; Seese AM; Power K; Abbasi B; Snuderl M; Chiang S; Kasif S; Jain RK Proc Natl Acad Sci U S A; 2014 May; 111(18):E1889-98. PubMed ID: 24753616 [TBL] [Abstract][Full Text] [Related]
27. A Review of the Clinical Applications of Artificial Intelligence in Abdominal Imaging. Mervak BM; Fried JG; Wasnik AP Diagnostics (Basel); 2023 Sep; 13(18):. PubMed ID: 37761253 [TBL] [Abstract][Full Text] [Related]
28. Current and emerging biomarkers in metastatic colorectal cancer. Lee MKC; Loree JM Curr Oncol; 2019 Nov; 26(Suppl 1):S7-S15. PubMed ID: 31819705 [TBL] [Abstract][Full Text] [Related]
29. Novel imaging techniques of rectal cancer: what do radiomics and radiogenomics have to offer? A literature review. Horvat N; Bates DDB; Petkovska I Abdom Radiol (NY); 2019 Nov; 44(11):3764-3774. PubMed ID: 31055615 [TBL] [Abstract][Full Text] [Related]
30. Biomarker concordance between primary colorectal cancer and its metastases. Bhullar DS; Barriuso J; Mullamitha S; Saunders MP; O'Dwyer ST; Aziz O EBioMedicine; 2019 Feb; 40():363-374. PubMed ID: 30733075 [TBL] [Abstract][Full Text] [Related]
31. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525 [TBL] [Abstract][Full Text] [Related]
32. Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. Loree JM; Kopetz S; Raghav KP J Gastrointest Oncol; 2017 Feb; 8(1):199-212. PubMed ID: 28280626 [TBL] [Abstract][Full Text] [Related]
33. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. Mao C; Wu XY; Yang ZY; Threapleton DE; Yuan JQ; Yu YY; Tang JL Sci Rep; 2015 Feb; 5():8065. PubMed ID: 25639985 [TBL] [Abstract][Full Text] [Related]
34. Pragmatic issues in biomarker evaluation for targeted therapies in cancer. de Gramont A; Watson S; Ellis LM; Rodón J; Tabernero J; de Gramont A; Hamilton SR Nat Rev Clin Oncol; 2015 Apr; 12(4):197-212. PubMed ID: 25421275 [TBL] [Abstract][Full Text] [Related]
36. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. Aisner DL; Nguyen TT; Paskulin DD; Le AT; Haney J; Schulte N; Chionh F; Hardingham J; Mariadason J; Tebbutt N; Doebele RC; Weickhardt AJ; Varella-Garcia M Mol Cancer Res; 2014 Jan; 12(1):111-8. PubMed ID: 24296758 [TBL] [Abstract][Full Text] [Related]
37. Biological resonance for cancer metastasis, a new hypothesis based on comparisons between primary cancers and metastases. Gao D; Li S Cancer Microenviron; 2013 Dec; 6(3):213-30. PubMed ID: 24214411 [TBL] [Abstract][Full Text] [Related]
38. Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis. Neumann J; Wehweck L; Maatz S; Engel J; Kirchner T; Jung A Virchows Arch; 2013 Oct; 463(4):509-23. PubMed ID: 23934607 [TBL] [Abstract][Full Text] [Related]
39. Targeted therapies in colorectal cancer-an integrative view by PPPM. Hagan S; Orr MC; Doyle B EPMA J; 2013 Jan; 4(1):3. PubMed ID: 23356214 [TBL] [Abstract][Full Text] [Related]
40. Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). García-Alfonso P; Salazar R; García-Foncillas J; Musulén E; García-Carbonero R; Payá A; Pérez-Segura P; Ramón y Cajal S; Navarro S; ; Clin Transl Oncol; 2012 Oct; 14(10):726-39. PubMed ID: 22855150 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]